1-14 of 14
Thomas S. Larsen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Trine Alma Knudsen, Dennis Lund Hansen, Lukas Frans Ocias, Ole Bjerrum, Mette Brabrand, Sarah Friis Christensen, Christina Schjellerup Eickhardt-Dalbøge, Christina Ellervik, Daniel El Fassi, Mikael Frederiksen, Lasse Kjær, Thomas Kielsgaard Kristensen, Torben A. Kruse, Morten Kranker Larsen, Torben Mourits-Andersen, Sören Möller, Ulrik Malthe Overgaard, Marianne Tang Severinsen, Vibe Skov, Anders Lindholm Sørensen, Jesper Stentoft, Jørn Starklint, Karin de Stricker, Mads Thomassen, Thomas S. Larsen, Hans C. Hasselbalch
Journal: Blood
Blood (2023) 142 (Supplement 1): 746.
https://doi.org/10.1182/blood-2023-173127
Published: 2023
Journal Articles

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Martin Hutchings, Abraham Avigdor, Anna Maria Sureda Balari, Maria José Terol, Francesc Bosch, Paolo Corradini, Thomas S. Larsen, Antonio Rueda Dominguez, Alan Skarbnik, Judit Mészáros Joergensen, David Lavie, Ronit Gurion, Pier Luigi Zinzani, Antonio Pinto, Raul Cordoba, Alessia Bottos, Donghang Li, James Relf, Audrey Filézac De L'Étang, Gila Sellam, Giuseppe Gritti
Journal: Blood
Blood (2023) 142 (Supplement 1): 4460.
https://doi.org/10.1182/blood-2023-174213
Published: 2023
Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Gerald Illerhaus, Andrés J.M. Ferreri, Mascha Binder, Peter Borchmann, Justin Hasenkamp, Stephan Stilgenbauer, Alexander Roeth, Thomas Weber, Gerlinde Egerer, Thomas Ernst, Bernd Hertenstein, Georg Lenz, Guido Kobbe, Uta Brunnberg, Christian Schmidt, Michael Kneba, Martin Dreyling, Robert Möhle, Jens Panse, Thomas Heinicke, Sebastian Schroll, Thomas S. Larsen, Hans Salwender, Ralph Naumann, Georg Hess, Lorenz Thurner, Tobias Pukrop, Ulrich Keller, Anne Kirsti Blystadt, Frank P. Kroschinsky, Francesca Re, Elisa Pulczynski, Lorella Orsucci, Lisa Pospiech, Martina Deckert, Maurilio Ponzoni, Julia Wendler, Elke Valk, Teresa Calimeri, Benjamin Kasenda, Martin Trepel, Heidi Fricker, Philipp von Gottberg, Elvira Burger, Gabriele Ihorst, Olga Grishina, Claudia Hader, Emanuele Zucca, Jürgen Finke, Elisabeth Schorb
Journal: Blood
Blood (2022) 140 (Supplement 2): LBA-3.
https://doi.org/10.1182/blood-2022-171733
Published: 2022
Journal Articles

A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

Thomas S. Larsen, Oliver Manzke, Daniel Leibovitz, Michael Arbushites
Journal: Blood
Blood (2022) 140 (Supplement 1): 12077–12078.
https://doi.org/10.1182/blood-2022-160319
Published: 2022
Journal Articles

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Trine A. Knudsen, Dennis Lund Hansen, Lukas Frans Ocias, Ole Weis Bjerrum, Mette Brabrand, Sarah F. Christensen, Christina Schjellerup S. Eickhardt-Dalbøge, Christina Ellervik, Daniel El Fassi, Mikael Frederiksen, Lasse Kjær, Thomas Kielsgaard Kristensen, Torben A. Kruse, Morten Kranker Larsen, Torben Mourits-Andersen, Ulrik Malthe Overgaard, Marianne Tang Severinsen, Vibe Skov, Anders Lindholm Sørensen, Jesper Stentoft, Jørn Starklint, Karin de Stricker, Mads Thomassen, Thomas S. Larsen, Hans Carl Hasselbalch
Journal: Blood
Blood (2022) 140 (Supplement 1): 1794–1796.
https://doi.org/10.1182/blood-2022-156445
Published: 2022
Journal Articles

Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Sirpa Leppa, Judit M. Jørgensen, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Mette Pedersen, Kristina Drott, Annika Pasanen, Kristiina Karihtala, Susanna Mannisto, Leo Meriranta, Bente Wold, Marianne Brodtkorb, Unn Merete Fagerli, Thomas S. Larsen, Lars Munksgaard, Kaisa Sunela, Øystein Fluge, Sirkku Jyrkkio, Peter de Nully Brown, Harald Holte
Journal: Blood
Blood (2022) 140 (Supplement 1): 1768–1769.
https://doi.org/10.1182/blood-2022-158183
Published: 2022
Journal Articles

Outcome after 3 rd Line Treatment for Diffuse Large B-Cell Lymphoma: A Danish Population-Based Study

Ahmed Ludvigsen Al-Mashhadi, Lasse Hjort Jakobsen, Peter de Nully Brown, Anne Ortved Gang, Anne-Luise Thorsteinsson, Kaziwa Rasoul, Judith Melchior Heissmann, Michael Buch Tøstesen, Mette Nieman Christoffersen, Jelena Jelicic, Jennifer Bøgh Jørgensen, Troels Thomsen, Andriette Dessau-Arp, Andreas PH Andersen, Mikael Frederiksen, Per Troellund Pedersen, Michael Roost Clausen, Judit Jørgensen, Christian Bjørn Poulsen, Tarec Christoffer Christoffer El-Galaly, Thomas S. Larsen
Journal: Blood
Blood (2022) 140 (Supplement 1): 6706–6707.
https://doi.org/10.1182/blood-2022-167897
Published: 2022
Journal Articles

Is It Possible to Omit Bone Marrow Biopsy in Diagnostic Workup in Patients with Newly Diagnosed Primary CNS Lymphoma? a Retrospective Analysis in the PET/CT Era

Jelena Jelicic, Dennis Lund Hansen, Sarah Sand Carlsen, Michael Thorsgaard, Ditte Hersby, Karina Kannik, Amalie Emilie Munksgaard, Thomas S. Larsen, Karen Juul-Jensen
Journal: Blood
Blood (2022) 140 (Supplement 1): 1334–1335.
https://doi.org/10.1182/blood-2022-165416
Published: 2022
Journal Articles

Impact of Trial Eligibility Criteria on Outcomes of 1,245 Patients with Follicular Lymphoma Treated in the Real-World Setting: A Danish Population-Based Study

Tine Bennedsen, Mikkel Simonsen, Peter de Nully Brown, Michael Roost Clausen, Andriette Dessau-Arp, Judit Jørgensen, Thomas S. Larsen, Christian Bjørn Poulsen, Lasse Hjort Jakobsen, Tarec Christoffer Christoffer El-Galaly
Journal: Blood
Blood (2022) 140 (Supplement 1): 3612–3614.
https://doi.org/10.1182/blood-2022-156376
Published: 2022
Journal Articles

Reproduktiv Patterns Among Non-Hodgkin Lymphoma Survivors By Subtype in Sweden, Denmark and Norway

Joshua P.P. Entrop, Caroline E. Weibull, Karin E. Smedby, Lasse Hjort Jakobsen, Andreas K. Oevlisen, Ingrid Glimelius, Anna Marklund, Thomas S. Larsen, Harald Holte, Alexander Fosså, Knut B. Smeland, Tarec Christoffer Christoffer El-Galaly, Sandra Eloranta
Journal: Blood
Blood (2022) 140 (Supplement 1): 1079–1081.
https://doi.org/10.1182/blood-2022-155919
Published: 2022
Journal Articles

Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial

Karin Fjorden, Sara Ekberg, Nevzeta Kuric, Karin Ekstroem Smedby, Ingemar Lagerlöf, MD, Thomas S. Larsen, MD, Judit M. Jørgensen, MD PhD, Peter de Nully Brown, MD PhD, Mats Jerkeman, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33.
https://doi.org/10.1182/blood-2020-133359
Published: 2020
Journal Articles

Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial)

Sirpa Leppa, MD, Judit Joergensen, Anne Tierens, Ingunn Østlie, Unn Merete Fagerli, Peter de Nully Brown, MD, Thomas S Larsen, Susanna Mannisto, Lars Munksgaard, Martin Maisenhölder, Kaija Vasala, Peter Meyer, Mats Jerkeman, Magnus Bjorkholm, Oystein Fluge, Sirkku Jyrkkio, Elisabeth Ralfkiaer, Signe Spetalen, Marja-Liisa Karjalainen-Lindsberg, Harald Holte
Journal: Blood
Blood (2016) 128 (22): 1854.
https://doi.org/10.1182/blood.V128.22.1854.1854
Published: 2016
Journal Articles

An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma

Tarec Christoffer El-Galaly, MD, Chan Yoon Cheah, Mette Dahl Bendtsen, Gita Thanarasjasingam, Roopesh Kansara, Kerry J Savage, MD, Joseph M. Connors, Neta Goldschmidt, MD, Adir Shaulov, Umar Farooq, MD, Laurie H Sehn, MD, Eldad J Dann, Carrie A Thompson, MD, Tsofia Inbar, Brian K Link, MD, Matthew J Maurer, MS, Inger Lise Gade, Maja Bech Juul, Jakob W Hansen, Staffan Holmberg, Thomas S Larsen, Stephen Opat, MD, N George Mikhaeel, John F Seymour, Michael Roost Clausen, MD, Daniel Smith, Michael Gilbertson, Grzegorz S Nowakowski, Sabrina Cordua, Martin Hutchings, Diego Villa
Journal: Blood
Blood (2016) 128 (22): 1874.
https://doi.org/10.1182/blood.V128.22.1874.1874
Published: 2016
Journal Articles

Quantitative PCR Assessment of JAK2 Mutational Status in Philadelphia-Chromosome Negative Chronic Myeloproliferative Disorders - The JAK2 V617F Mutation Is an Event in an Early Stem Cell and the Clonal Involvement of Different Haematopoietic Cells Varies between Individual Patients.

Thomas S. Larsen, MD, Hans C. Hasselbalch, M.D DMsc, Niels Pallisgaard
Journal: Blood
Blood (2006) 108 (11): 3602.
https://doi.org/10.1182/blood.V108.11.3602.3602
Published: 2006